IN THE UNITED STATES PATENT AND TRADEMARK OFFICE (Case No 05-988-G; (EX03-089C-US))

In the	Application of:	
)	
	Kadyk <i>et al.</i>	
)	Examiner: Cheu, Changhwa
Serial	No.: 10/535,571	_
)	Group Art Unit: 1641
Filing Date: June 5, 2008		
)	Confirmation No. 8822
For:	MAPKs as Modifiers of the RAC, AXIN,)	
	and Beta-Catenin Pathways and Methods)	
	of Use	

RESPONSE TO RESTRICTION REQUIRMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

This paper is filed in response to the restriction requirement mailed on August 18, 2010, in the above-mentioned application. Applicants submit herewith a petition for a one month extension of time and the appropriate fee. It is believed that no further fee is due in connection with this filing. However, if a fee is due the Commissioner is authorized to charge our deposit account 13-2490.

With respect to the restriction requirement, Applicants hereby elect with traverse Group I, allegedly drawn to a method of identifying a candidate RAC, AXIN, and Beta-Catenin pathway agent, for prosecution on the merits. The claims readable thereon are claims 1-22.

Applicants note that the reference cited in the Restriction Requirement (MacDonald et al., Nature Genetics, 29:143-152 (2001)), concerns a MAPKAP gene, which gene is structurally and functionally different from the MAPK and MINK genes used in the present invention.